ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) (Except for Per Share Data or where otherwise noted, Numbers are in Thousands) announced best ever Company quarterly and annual fiscal year results, topping one hundred million in net revenue during the quarter for the first time. The Company recorded Q4FY09 revenues of $102,312, the best ever quarter in terms of revenues in corporate history and an increase of 26% over the $81,237 recorded in the fourth quarter, fiscal year 2008. Net income before taxes in Q4FY09 totaled $12,756; an increase of 37% compared with net income before taxes of $9,335 in Q4FY08. Net income after tax for Q4FY09 totaled $7,183 or $.51 per share as compared with $5,245 or $.38 per share in the corresponding quarter in FY08. Gross profits on revenues for the current quarter were $51,877 resulting in a margin for gross profit on revenues of 51%, versus the $40,801 reported for the prior fiscal year fourth quarter, resulting in a margin of 50%. Revenue per patient for the fourth quarter of the current fiscal year was $77.39, a decrease of 1% from the $78.22 reported for the same quarter of the prior fiscal year, and, sequentially, a slight decrease from the $77.61 reported in Q3FY09. The number of patients served increased 27% to 1,309 in the current quarter from the prior year fourth quarter total of 1,029. Esoteric business for the Company remained at 53% of revenues for the fourth quarter of the current fiscal year and Days Sales Outstanding (DSO) remained at 95 days, both metrics remaining the same as at the end of third quarter of the current year.
